Electra Therapeutics priced and launched an upsized IPO on Nasdaq, raising $350 million to help fund development of its inflammation-focused pipeline. The listing follows a wave of larger-than-expected biotech IPOs and adds another inflammation entrant to the public markets. The proceeds are positioned to support Electra’s transition from clinical-stage development toward commercial readiness, aligning with investor appetite for companies with differentiated mechanism-of-action approaches in immunology and inflammation. Electra joins a broader 2026 pattern in which many biotechs are tapping the public markets at scale, with multiple issuers raising more than $300 million. The market backdrop has been sensitive to trial readouts and valuation discipline, but strong deal flow has persisted into the back half of the year. For industry watchers, Electra’s oversubscribed debut underscores that investors remain willing to underwrite inflammation franchises when early clinical differentiation and funding needs are clear.